A new, light, accurate, fast, high-sensitivity handheld device significantly reduce the false-negative antibody detection rate of COVID-19

Kaohsiung Municipal Siao-Kang hospital and SpectroChip Inc. collaborate to Create World-Leading Quantitative Screening Instrument for COVID-19 - The ONE. There are several advantages. "Fast": 10-15 minutes from sample collection to fast screening results; "Accurate": accurate quantification of antibodies (IgG/IgM), which is 100 times more sensitive than the existing fast sieving test and can rule out most pseudonegative misjudgments. "Wide": Handheld size, portable and convenient for expanding the inspection field; "Instant": Inspection results are returned to the cloud via mobilephone app. to cloud database for real-time tracking of the epidemic. For patients with suspected COVID19 infection, home confinement, or follow-up of confirmed patients, rapid screening can help determine the cause of a patient's illness. In addition, the hospitalization time in the hospital should be reduced as a reference for the suitability of discharge. In the future, we will be able to conduct large-scale medical research and field applications.

Epidemic Prevention Advantage：
"Fast": 10-15 minutes from sample collection to fast screening results.
"Accurate": accurate quantification of antibodies (IgG/IgM), which is 100 times more sensitive than the existing fast sieving test and can rule out most pseudonegative misjudgments.
"Wide": Handheld size, portable and convenient for expanding the inspection field.
"Instant": Inspection results are returned to the cloud via mobilephone app. to cloud database for real-time tracking of the epidemic.

Collaboration Options：Patent, Product, Technology Licensing